Grover SA - Search Results

1

Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort.

Grover SA, Palmer CS, Coupal L. Grover SA, et al. Arch Intern Med. 1994 Mar 28;154(6):679-84. Arch Intern Med. 1994. PMID: 8129502

2

The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease.

Grover SA, Lowensteyn I, Kaouache M, Marchand S, Coupal L, DeCarolis E, Zoccoli J, Defoy I. Grover SA, et al. Arch Intern Med. 2006 Jan 23;166(2):213-9. doi: 10.1001/archinte.166.2.213. Arch Intern Med. 2006. PMID: 16432091

3

Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial.

Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, Boudreau G; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Grover SA, et al. Arch Intern Med. 2007 Nov 26;167(21):2296-303. doi: 10.1001/archinte.167.21.2296. Arch Intern Med. 2007. PMID: 18039987 Clinical Trial.

4

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

Grover SA, Coupal L, Hu XP. Grover SA, et al. JAMA. 1995 Sep 13;274(10):801-6. JAMA. 1995. PMID: 7650803

5

Risk-benefit assessment of drug treatment to prevent coronary heart disease. Estimating the benefits of risk factor modification.

Grover SA, Coupal L. Grover SA, et al. Drug Saf. 1994 Apr;10(4):301-9. doi: 10.2165/00002018-199410040-00004. Drug Saf. 1994. PMID: 8018302 Review.

6

Life expectancy following dietary modification or smoking cessation. Estimating the benefits of a prudent lifestyle.

Grover SA, Gray-Donald K, Joseph L, Abrahamowicz M, Coupal L. Grover SA, et al. Arch Intern Med. 1994 Aug 8;154(15):1697-704. Arch Intern Med. 1994. PMID: 8042886

7

Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Grover SA, et al. Arch Intern Med. 1998 Mar 23;158(6):655-62. doi: 10.1001/archinte.158.6.655. Arch Intern Med. 1998. PMID: 9521231

8

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Grover SA, Coupal L, Paquet S, Zowall H. Grover SA, et al. Arch Intern Med. 1999 Mar 22;159(6):593-600. doi: 10.1001/archinte.159.6.593. Arch Intern Med. 1999. PMID: 10090116

9

Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease.

Perreault S, Dorais M, Coupal L, Paradis G, Joffres MR, Grover SA. Perreault S, et al. Among authors: grover sa. CMAJ. 1999 May 18;160(10):1449-55. CMAJ. 1999. PMID: 10352634 Free PMC article.

10

Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.

Grover SA, Dorais M, Paradis G, Fodor JG, Frohlich JJ, McPherson R, Coupal L, Zowall H. Grover SA, et al. CMAJ. 2000 Nov 14;163(10):1263-9. CMAJ. 2000. PMID: 11107461 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters